Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Myeloproliferative Disorders 4Primary Myelofibrosis 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Inhibition, Psychological 1Hodgkin Disease 1Graft vs Host Disease 1B-cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 62Rituximab 47fludarabine 35fludarabine phosphate 27obinutuzumab 17Mycophenolic Acid 16ibrutinib 15Whole-Body Irradiation 15Lenalidomide 15Specimen Handling 14Prednisone 14venetoclax 13pirtobrutinib 13Etoposide 13Doxorubicin 13pembrolizumab 12Tacrolimus 12Magnetic Resonance Spectroscopy 11Granulocyte Colony-Stimulating Factor 11Filgrastim 11Biopsy 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Melphalan 10X-Rays 9Bendamustine Hydrochloride 9polatuzumab vedotin 8glofitamab 8acalabrutinib 8Immunotherapy, Adoptive 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × itacitinib × 1 year × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡